Intravenous Drip Therapies in the Initial Management of Acute STEMI

Anticoagulation

• Unfractionated heparin (UFH) is the preferred IV anticoagulant for primary PCI. A weight‑adjusted bolus (≈ 70 U/kg without a maximum dose) followed by continuous infusion should be started immediately after STEMI diagnosis while arranging catheterization. ACC/AHA guideline. 1

Antiplatelet Therapy

• Aspirin 162–325 mg should be given immediately at first medical contact, preferably chewed for rapid absorption; IV aspirin 250 mg is an acceptable alternative when oral administration is impossible. ACC/AHA guideline. 1

Glycoprotein IIb/IIIa Inhibitors

• GP IIb/IIIa inhibitors (e.g., abciximab or eptifibatide) may be administered as IV infusions during primary PCI in high‑risk patients. In organized STEMI networks they were used in about 70 % of cases, typically initiated in the catheterization laboratory at the discretion of the interventionalist. ACC/AHA guideline. 1

Beta‑Blocker Considerations

• IV beta‑blockers should not be given routinely in the acute STEMI setting. They are contraindicated in patients with hypotension or hemodynamic instability (ESC), acute heart failure (ESC), high‑grade AV block or marked bradycardia (ESC), and cardiogenic shock (ACC/AHA). [2][3]
• Oral beta‑blockers should be started within 24 h in hemodynamically stable patients and continued long‑term. (Guideline context inferred from the same sources.)

Oxygen Therapy

• Routine supplemental oxygen is not recommended unless peripheral oxygen saturation is < 90 %. In non‑hypoxemic patients, routine oxygen provides no benefit and may be harmful. ESC guideline. 2

Timing of Reperfusion

• Primary PCI should be performed within 90 minutes of first medical contact when the patient presents to a PCI‑capable facility.
• If transfer to a PCI‑capable centre is required, door‑to‑balloon time should not exceed 120 minutes.
• When PCI cannot be achieved within these windows, fibrinolysis should be administered within 30 minutes of diagnosis. These time targets are core quality metrics for STEMI care. ACC/AHA (2017) and ESC (2012) guidelines. [3][4]

Use of Other IV Drips

• Morphine or other opioids should be reserved for severe chest pain not relieved by nitrates; routine use is discouraged. ACEP (Emergency Medicine) recommendation. 5
• IV nitroglycerin is not a mandatory drip for all STEMI patients; it should be given only for persistent chest pain, hypertension, or pulmonary edema in the absence of hypotension. ESC guideline. 2

All statements are derived from cited guideline sources and reflect the current evidence‑based recommendations for the initial intravenous management of adult patients with acute ST‑segment‑elevation myocardial infarction.

Acute Coronary Syndrome with ST-Segment Elevation Management

Antithrombotic Therapy

• The American College of Cardiology recommends a loading dose of Ticagrelor 180 mg orally as the first-line treatment, to be administered as soon as possible, ideally in the emergency medical services vehicle or emergency department before catheterization 6, 7
• The European Society of Cardiology recommends Aspirin 75-100 mg orally to be administered simultaneously with ticagrelor or prasugrel to all patients without contraindications 8, 7
• Clopidogrel is only used for fibrinolysis or when ticagrelor or prasugrel are contraindicated or unavailable 6, 9

Anticoagulant Therapy

• The American Heart Association recommends Unfractionated Heparin (UFH) as the preferred anticoagulant for primary percutaneous coronary intervention (PCI), administered as a weight-adjusted bolus with subsequent infusion 6, 7
• The European Heart Journal recommends Enoxaparin (intravenously with subsequent subcutaneous administration) as the preferred anticoagulant for patients receiving fibrinolysis 8, 7, 9

Fibrinolytic Therapy

• The American College of Cardiology recommends Fibrin-specific agents (tenecteplase, alteplase, or reteplase) as the preferred fibrinolytic strategy when primary PCI is not available in a timely manner 7, 9

Post-PCI Supportive Therapy

• The European Society of Cardiology recommends Ticagrelor 90 mg twice daily for 12 months (class I recommendation) 8, 6
• The American Heart Association recommends Aspirin 75-100 mg daily indefinitely 8, 6, 7

Additional Mandatory Therapy

• The European Society of Cardiology recommends High-intensity statin therapy as soon as possible, with a target LDL-C level <1.8 mmol/L 8, 7
• The American College of Cardiology recommends ACE inhibitors within the first 24 hours for patients with heart failure, left ventricular ejection fraction (LVEF) <40%, diabetes, or anterior infarction 8, 7
• The European Heart Journal recommends Beta-blockers orally for patients with heart failure and/or LVEF <40% 8, 7
• The American Heart Association recommends Mineralocorticoid receptor antagonists for patients with LVEF <40% and heart failure or diabetes 8, 7

Critical Errors to Avoid

• Do not use fondaparinux as the sole anticoagulant during PCI, as it increases the risk of catheter thrombosis and requires additional UFH 7, 9
• Do not switch between enoxaparin and UFH in the acute phase, as it increases the risk of bleeding 6
• Do not use clopidogrel instead of ticagrelor or prasugrel for primary PCI, as clopidogrel is reserved for patients with fibrinolysis 6, 9
• Avoid intravenous beta-blockers in patients with hypotension, acute heart failure, AV block, or marked bradycardia 8